Asset Details
Do you wish to reserve the book?
Low dose-olanzapine-induced neuroleptic malignant syndrome in adolescent : and literature review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Low dose-olanzapine-induced neuroleptic malignant syndrome in adolescent : and literature review
Do you wish to request the book?
Low dose-olanzapine-induced neuroleptic malignant syndrome in adolescent : and literature review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Low dose-olanzapine-induced neuroleptic malignant syndrome in adolescent : and literature review
2018
Overview
Neuroleptic malignant syndrome is a rare but potentially lethal
condition associated with neuroleptic medications. It is characterized
by high temperature, extrapyramidal symptoms, autonomic variability,
and changes in consciousness. Although olanzapine is an atypical
antipsychotic, which exhibits more affi nity to serotonin receptors than
to dopamine receptors, atypical antipsychotics (like olanzapine) can
cause \"typical and atypical\" forms of neuroleptic malignant syndrome.
Previous reports of neuroleptic malignant syndrome associated
with olanzapine have described patients who had been previously
treated with other antipsychotic medications, patients who had
previous incidents of neuroleptic malignant syndrome caused by
other neuroleptics, or patients treated with olanzapine and another
neuroleptic. This article describes a case of neuroleptic malignant
syndrome linked to olanzapine in a male adolescent, 17-year old, who
had not previously been treated with antipsychotic medications. He
presented in an agitated state, with acute onset of fever, catatonia
for 15 days, and severe negativism, refusal to eat, mutism, and brief
episodes of abrupt psychomotor agitation and aggression toward his
family.
